A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Dose Escalation Study to Evaluate the Safety and Pharmacokinetics/pharmacodynamics of PF-06835375, a C-X-C Chemokine Receptor Type 5 Directed Antibody, in Patients with Systemic Lupus Erythematosus or Rheumatoid Arthritis

Stanley Cohen,Jean S. Beebe,Vishala Chindalore,Shunjie Guan,Mina Hassan-Zahraee, Madhurima Saxena,Li Xi,Craig Hyde, Sarita Koride,Robert Levin,Shannon Lubaczewski,Mikhail Salganik,Abigail Sloan,Erin Stevens,Elena Peeva,Michael S. Vincent,David A. Martin,Myron Chu

Arthritis Research & Therapy（2024）

Cited 0|Views13

Key words

CXCR5,PF-06835375,Safety,Efficacy,Systemic lupus erythematosus,Rheumatoid arthritis,B-cell depletion,Follicular helper T cells depletion,Pharmacokinetics,Pharmacodynamics

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined